SCHEMBL13837656

SCHEMBL13837656

CC(C)COC(=O)c1c(-c2cc(Cl)cc(Cl)c2)csc1N

nearest known ligand 0.57

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PRKCZ Q05513 12/20 0.57
ALDH1A1 P00352 7/20 0.49
HSD17B10 Q99714 5/20 0.49
HPGD P15428 3/20 0.49
MAPT P10636 5/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
USP2 O75604 1/20 0.48
ALOX15 P16050 1/20 0.48
PRKCI P41743 3/20 0.46
MAPK1 P28482 4/20 0.45
POLB P06746 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
LMNA P02545 1/20 0.44
TSHR P16473 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8288641 0.80 PRKCZ (0.75) PRKCZALDH1A1HSD17B10HPGDMAPT
SCHEMBL689025 0.74 PRKCZ (0.73) PRKCZALDH1A1HSD17B10HPGDMAPT
SCHEMBL690269 0.73 PRKCZ (1.00) PRKCZALDH1A1HSD17B10HPGDMAPT
SCHEMBL5919161 0.72 PRKCZ (0.75) PRKCZALDH1A1HSD17B10HPGDMAPT
SCHEMBL12271891 0.70 PRKCZ (0.68) PRKCZALDH1A1HSD17B10HPGDMAPT
SCHEMBL1554707 0.70 PRKCZ (0.75) PRKCZALDH1A1HSD17B10HPGDMAPT
SCHEMBL18956157 0.70 PRKCZ (0.74) PRKCZALDH1A1HSD17B10HPGDMAPT
SCHEMBL8289403 0.69 PRKCZ (0.66) PRKCZALDH1A1HSD17B10HPGDMAPT
SCHEMBL25487711 0.69 PRKCZ (0.73) PRKCZALDH1A1HSD17B10HPGDMAPT
SCHEMBL13837659 0.69 ALDH1A1 (0.69) PRKCZALDH1A1HSD17B10HPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8889672-B2 Compounds, formulations, and methods of protein kinase C inhibition THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2014-11-18 US disclosed
US-8889672-B2 Compounds, formulations, and methods of protein kinase C inhibition THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2014-11-18 US disclosed
US-20120302561-A1 Compounds, Formulations, and Methods of Protein Kinase C Inhibition THE PENN STATE RESEARCH FOUNDATION (US) 2012-11-29 US disclosed
US-20120302561-A1 Compounds, Formulations, and Methods of Protein Kinase C Inhibition THE PENN STATE RESEARCH FOUNDATION (US) 2012-11-29 US disclosed
WO-2012149452-A1 COMPOUNDS, FORMULATIONS, AND METHODS OF PROTEIN KINASE C INHIBITION REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2012-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120302561-A1 Compounds, Formulations, and Methods of Protein Kinase C Inhibition PRKCA, PRKCH, PRKCI PRKCZ 5/4885ALDH1A1 4665/4885HSD17B10 3787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.